

# A mechanism of inhibition of aflatoxin B<sub>1</sub> hepatocarcinogenesis by $\beta$ -naphthoflavone pretreatment of rats

K. Santhanam<sup>1,2</sup>, Lingling Ho<sup>1</sup>, Prathima Gopalan-Kriczky<sup>1</sup> and Prabhakar D. Lotlikar<sup>1,3</sup>

1 Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA 19140, U.S.A.

2 Present address: Defense Food Research Laboratory, Mysore 570011, India.

3 To whom requests for reprints should be sent.

Accepted 30 August 1996

Abbreviations: AFB<sub>1</sub>, aflatoxin B<sub>1</sub>; AFB<sub>1</sub>-epoxide, aflatoxin B<sub>1</sub>-8,9-oxide; AFQ<sub>1</sub>, aflatoxin Q<sub>1</sub>; AFM<sub>1</sub>, aflatoxin M<sub>1</sub>; AFP<sub>1</sub>, aflatoxin P<sub>1</sub>; AFB<sub>1</sub>-SG, aflatoxin B<sub>1</sub>-glutathione conjugate; BNF,  $\beta$ -naphthoflavone; GST, glutathione S-transferase; PB, phenobarbital

## Abstract

Pretreatment with  $\beta$ -naphthoflavone (BNF) inhibits aflatoxin B<sub>1</sub> (AFB<sub>1</sub>) hepatocarcinogenesis in the rat by stimulation of aflatoxin M<sub>1</sub> (AFM<sub>1</sub>) hydroxylation. We have now examined the effect of BNF pretreatment of rats on AFB<sub>1</sub>-hydroxylations, AFB<sub>1</sub>-DNA binding and AFB<sub>1</sub>-glutathione (AFB<sub>1</sub>-SG) conjugation in liver *in vitro*, *in vivo* and in isolated hepatocytes. Male Fischer rats were injected i.p. with either corn oil or BNF (25 mg/kg body weight) 24 h before for *in vitro* and in isolated hepatocyte studies. Cytochrome P-450 contents in BNF-treated rat liver microsomes and hepatocytes were 170% and 200% of controls, respectively. At two AFB<sub>1</sub> concentrations (2  $\mu$ M and 100  $\mu$ M), AFB<sub>1</sub>-epoxidation measured as AFB<sub>1</sub>-DNA binding and AFM<sub>1</sub> hydroxylation were 60% and 300% of controls, respectively. At low AFB<sub>1</sub> level (33 nM), AFB<sub>1</sub>-binding and AFM<sub>1</sub> formation in BNF-treated hepatocytes were 40% and 225% of controls, respectively. Formation of AFB<sub>1</sub>-SG, aflatoxin Q<sub>1</sub> and aflatoxin P<sub>1</sub> were not affected significantly. Hepatic nuclear AFB<sub>1</sub>-DNA binding 2 h after i.p. injection of 0.4 mg [<sup>3</sup>H]AFB<sub>1</sub>/kg body wt. in BNF-treated rats was 60% of controls. The overall data indicate that lower AFB<sub>1</sub>-DNA binding in addition to higher inactivation via AFM<sub>1</sub> hydroxylation are responsible for the inhibition of AFB<sub>1</sub> hepatocarcinogenesis by BNF pretreatment of rats. It is suggested that this inhibition of AFB<sub>1</sub>-DNA binding may be a direct result of lower levels of constitutive

cytochromes P-450 responsible for AFB<sub>1</sub>-epoxidation.

**Keywords:** aflatoxin B<sub>1</sub>-DNA binding; AFB<sub>1</sub>-epoxide; aflatoxin M<sub>1</sub> hydroxylation;  $\beta$ -naphthoflavone

## Introduction

Epidemiological data have indicated that contamination of food with aflatoxin B<sub>1</sub> (AFB<sub>1</sub>) may be an important etiological factor in human liver cancer in several parts of Africa and Asia (Van Rensburg *et al.*, 1985; Autrup *et al.*, 1987; Ross *et al.*, 1992). Rat has been shown to be a very sensitive laboratory animal species to AFB<sub>1</sub> hepatocarcinogenesis (Newberne and Butler, 1969). It is well established that AFB<sub>1</sub> undergoes cytochrome P-450 dependent metabolic activation to form an ultimate reactive metabolite, AFB<sub>1</sub>-8,9-oxide (AFB<sub>1</sub>-epoxide) which interacts covalently with cellular macromolecules including DNA. It is believed that AFB<sub>1</sub>-DNA interaction is responsible for the initiation of AFB<sub>1</sub> hepatocarcinogenesis (Miller and Miller, 1977; Essigmann *et al.*, 1977). In addition to AFB<sub>1</sub>-epoxidation, AFB<sub>1</sub> is oxidized via cytochrome P-450 dependent enzymes to several hydroxylated metabolites viz. aflatoxin Q<sub>1</sub> (AFQ<sub>1</sub>), aflatoxin M<sub>1</sub> (AFM<sub>1</sub>) and aflatoxin P<sub>1</sub> (AFP<sub>1</sub>) which are non carcinogenic (Wong and Hsieh, 1976; Gurtoo *et al.*, 1978).

Carcinogenicity of AFB<sub>1</sub> is inhibited by pretreatment of rats with either phenobarbital (PB), several antioxidants or  $\beta$ -naphthoflavone (BNF). This inhibition is shown to be due to induction of either cytochromes P-450 phase I enzymes, or glutathione S-transferases (GSTs) phase II enzymes or both (Gurtoo and Dahms, 1979; Degen and Neumann, 1981; Gurtoo *et al.*, 1985; Mandel *et al.*, 1987; Jhee *et al.*, 1989; Lotlikar, 1989; Lotlikar *et al.*, 1989; Kensler, 1994; Stresser *et al.*, 1994a, 1994b). Earlier studies indicated that BNF inhibition of AFB<sub>1</sub> hepatocarcinogenesis in the rat is primarily due to the induction of cytochrome P-450 which specifically enhances AFB<sub>1</sub> inactivation via AFM<sub>1</sub> hydroxylation (Gurtoo *et al.*, 1985). This report confirms earlier observations of Gurtoo *et al.* (1985) indicating enhanced AFM<sub>1</sub> hydroxylation and also provides additional data both *in vivo* and *in vitro* which indicate that BNF pretreatment of rats inhibits hepatic AFB<sub>1</sub>-DNA binding. This inhibition of AFB<sub>1</sub>-DNA binding may be a direct result of lower levels of constitutive cytochromes P-450 responsible for AFB<sub>1</sub>-epoxidation.

## Materials and Methods

### Chemicals

Non-radioactive AFB<sub>1</sub>, AFM, AFQ<sub>1</sub>, AFP<sub>1</sub>, GSH, calf thymus DNA, bovine pancreatic RNase, bovine serum albumin, BNF, collagenase (type IV),  $\beta$ -glucuronidase (type H<sub>1</sub>), and sulfatase (type H-1) were obtained from Sigma Chemical Co. (St. Louis, MO). Radioactive [<sup>3</sup>H]AFB<sub>1</sub> (30 Ci/mmol) was purchased from Moravak Biochemicals, Inc. (Brea, CA). Scintillation fluid 'Scintiverse II' was obtained from National Diagnostic Co. (Manville, NJ). Radioactive [<sup>3</sup>H]AFB<sub>1</sub> was diluted with non-radioactive AFB<sub>1</sub> in dimethyl sulfoxide to obtain the required specific activity. C<sub>18</sub>- $\mu$  Bondapak column (0.39 x 30 cm) and C<sub>18</sub>-Sep-pak cartridges were obtained from Waters Associates, (Milford, MA). NADPH was purchased from Boehringer Mannheim Biochemicals (Indianapolis, IN). HPLC grade CHCl<sub>3</sub>, methanol and ethyl acetate were obtained from Fisher Scientific Co. (Fairlawn, NJ).

### Animals and treatment

Male Fischer rats (175-200g) obtained from Charles River Breeding Laboratories (Wilmington, MA) were maintained on a Purina rodent laboratory chow and given tap water for drinking for a week before use. Some animals were injected i.p. with BNF (2.5 mg/100 g body weight dissolved in corn oil) 24 h before sacrifice. Control animals were injected i.p. with corn oil alone. For *in vitro* studies, liver microsomes and cytosols were prepared as described previously (Lotlikar *et al.*, 1989).

### Microsome-mediated hydroxylation of AFB<sub>1</sub> and binding to exogenous DNA

The incubation medium contained 100 mM phosphate buffer, pH 7.4, 2 mM NADPH, 1  $\mu$ Ci [<sup>3</sup>H]AFB<sub>1</sub> containing either 2 or 100 nmol AFB<sub>1</sub> dissolved in 0.02 ml dimethyl sulfoxide, 100 mM sucrose, liver microsomes containing 1 mg protein and 0.2 mg native calf thymus DNA in a total volume of 1.0 ml. After incubation of duplicate samples in air for 30 min at 37°C, 1 ml solution containing 0.8 mg calf thymus DNA was added as a carrier to each sample. Out of 2 ml a 1-ml portion was drawn for isolation of DNA and another portion was used for extraction of hydroxylated metabolites of AFB<sub>1</sub>. Isolation of DNA and quantitation of DNA by UV spectrophotometry were as described previously (Daoud and Irving, 1977; Lotlikar *et al.*, 1989). Two aliquots of isolated DNA were taken for radioactivity measurements by using 5 ml of Scintiverse II. Samples were counted in a LKB 1219 Rackbeta liquid scintillation spectrometer with an efficiency of about 45% for <sup>3</sup>H counting. Results of [<sup>3</sup>H]AFB<sub>1</sub> binding to DNA are corrected for DNA recovery and are

expressed as pmol [<sup>3</sup>H]AFB<sub>1</sub> bound/mg DNA/mg protein/30 min.

Extraction and separation of hydroxy metabolites on HPLC C<sub>18</sub>- $\mu$  Bondapak column were as described previously (Lotlikar *et al.*, 1989). Results are expressed as pmol of AFP<sub>1</sub>, AFM<sub>1</sub> and AFQ<sub>1</sub> formed/mg protein/30 min.

### AFB<sub>1</sub>-DNA binding, AFB<sub>1</sub>-GSH (AFB<sub>1</sub>-SG) conjugation and hydroxylation of AFB<sub>1</sub> during incubation of isolated hepatocytes

Hepatocytes were isolated by the collagenase method of Moldeus *et al.* (1978) as described previously (Lotlikar *et al.*, 1989). Duplicate aliquots of hepatocytes (2 x 10<sup>7</sup> cells/5ml) were incubated in the presence of modified Hank's balanced salt solution containing 2 mM CaCl<sub>2</sub>, 25 mM Hepes buffer (pH 7.4), 0.5% serum albumin and two levels of AFB<sub>1</sub> (33 nM and 2  $\mu$ M) containing 1  $\mu$ Ci of [<sup>3</sup>H]AFB<sub>1</sub> per ml in 95% O<sub>2</sub>-5% CO<sub>2</sub> at 37°C for 1 h. AFB<sub>1</sub> was dissolved in dimethyl sulfoxide and final concentration of dimethyl sulfoxide was 2.0% (v/v). After incubation, cells were homogenized and nuclei were sedimented at 600 g for 10 min. Nuclear supernatants were used for extraction, separation and quantitation of free and conjugated hydroxy metabolites and AFB<sub>1</sub>-SG conjugate, as described by our published procedures (Lotlikar *et al.*, 1989).

Isolation of DNA from the sedimented nuclei was as described previously (Lotlikar *et al.*, 1989). Aliquots of isolated DNA were taken for colorimetric determination of DNA (Burton, 1956) and for radioactivity measurements. Results of [<sup>3</sup>H]AFB<sub>1</sub> bound to DNA are corrected for DNA recovery, which was 50-60% and are expressed in terms of pmol of AFB<sub>1</sub> bound per mg DNA per h.

### AFB<sub>1</sub> binding to hepatic nuclear DNA *in vivo*

For these studies rats, 24 hr after i.p. injection with either corn oil or BNF were injected i.p. with [<sup>3</sup>H]AFB<sub>1</sub> (40  $\mu$ g AFB<sub>1</sub> containing 10  $\mu$ Ci [<sup>3</sup>H]AFB<sub>1</sub> in 0.2 ml dimethyl sulfoxide/100 g body weight) 2 h before sacrifice. Isolation of DNA from the hepatic nuclear pellet and quantitation of AFB<sub>1</sub>-DNA binding were as described previously (Lotlikar *et al.*, 1989).

### Miscellaneous assays

Cytochrome P-450 content in liver microsomes and isolated hepatocytes was determined by the method of Omura and Sato (1984). Protein in microsomes and cytosol was assayed by the Lowry method with bovine serum albumin as the standard (Lowry *et al.*, 1951). The significance of the data was statistically evaluated by using student's *t*-test; *P* values less than 0.05 were considered to be highly significant.

**Table 1.** Effect of BNF pretreatment of rats on hepatic microsomal cytochrome P-450 content and cytochromes P-450 mediated hydroxylations of AFB<sub>1</sub> and AFB<sub>1</sub> binding to exogenous DNA. Animals were injected i.p. with either corn oil or 2.5 mg BNF/100 g body weight. 24 h before sacrifice. Isolation of hepatic microsomes, the incubation medium for microsome-mediated AFB<sub>1</sub> binding to calf thymus DNA and formation of hydroxy metabolites of AFB<sub>1</sub> and other experimental details were as described in 'Materials and Methods'. Results are given as means  $\pm$  SD of three analyses on individual livers from 3 animals.

BNF Pretreatment	Cytochrome P-450 content (nmol/mg protein)	AFB <sub>1</sub> concentration ( $\mu$ M)	Metabolites of AFB <sub>1</sub> (pmol/mg protein/30 min)			
			AFB <sub>1</sub> -DNA	AFQ <sub>1</sub>	AFM <sub>1</sub>	AFP <sub>1</sub>
-	0.30 $\pm$ 0.03	2	58 $\pm$ 4	32 $\pm$ 6	120 $\pm$ 10	55 $\pm$ 15
		100	1,350 $\pm$ 55	1,320 $\pm$ 300	3,000 $\pm$ 200	270 $\pm$ 20
+	0.52 $\pm$ 0.04 <sup>a</sup>	2	37 $\pm$ 5 <sup>a</sup>	47 $\pm$ 9	340 $\pm$ 50 <sup>a</sup>	50 $\pm$ 10
		100	820 $\pm$ 80 <sup>a</sup>	1,430 $\pm$ 120	9,050 $\pm$ 1,100 <sup>a</sup>	290 $\pm$ 100

<sup>a</sup> Data highly significant with *P* values  $<$  0.01 when compared with respective data of animals without BNF pretreatment.

**Table 2.** AFB<sub>1</sub>-DNA binding, AFB<sub>1</sub>-SG conjugation and hydroxy metabolite formation during AFB<sub>1</sub> metabolism with isolated hepatocytes from control and BNF treated rats. Isolation and incubation of hepatocytes with either 33 nM or 2  $\mu$ M [<sup>3</sup>H]AFB<sub>1</sub> for 1 h were as described in 'Materials and Methods'. Metabolites were calculated for 10<sup>8</sup> cells corresponding to 1 mg DNA/h. Results of [33 nM] AFB<sub>1</sub> incubations are expressed as mean  $\pm$  SD of three separate analyses on individual livers from three animals whereas data of 2  $\mu$ M AFB<sub>1</sub> incubations are averages of duplicate samples from one liver with variations of  $<$  10%.

BNF Pretreatment	AFB <sub>1</sub>	AFB <sub>1</sub> -DNA	AFB <sub>1</sub> -SG	AFQ <sub>1</sub>	AFM <sub>1</sub>	AFP <sub>1</sub>
		pmol/10 <sup>8</sup> cells/h				
-	33 nM	8.6 $\pm$ 2.1	14.0 $\pm$ 4.5	14.5 $\pm$ 5.0	46.5 $\pm$ 3.5	24.0 $\pm$ 8.0
+		3.3 $\pm$ 0.4 <sup>a</sup>	18.7 $\pm$ 2.7	18.8 $\pm$ 2.8	104 $\pm$ 16 <sup>b</sup>	16.0 $\pm$ 6.0
-	2 $\mu$ M	404	810	1,350	4,875	2,730
+		271	1,400	1,900	7,950	1,925

<sup>a</sup> Data highly significant with *P* values  $<$  0.05 when compared with data of animals without BNF pretreatment.

<sup>b</sup> Data highly significant with *P* value  $<$  0.01 when compared with data of animals without BNF pretreatment.

## Results

Data on hepatic microsomal cytochrome P-450 content and cytochromes P-450 mediated hydroxylations of AFB<sub>1</sub> and AFB<sub>1</sub> binding to exogenous calf thymus DNA from control and BNF pretreated rats are presented in Table 1. Total cytochrome P-450 content in microsomes from BNF treated rats was increased by about 70% of control levels. At 2  $\mu$ M AFB<sub>1</sub> concentration, in addition to AFM<sub>1</sub>, the formation of AFQ<sub>1</sub> appeared to be substantial. At both AFB<sub>1</sub> concentrations, only AFM<sub>1</sub> formation was increased 2-3 fold by microsomes from BNF pretreated rats. In contrast, AFB<sub>1</sub>-epoxidation as measured by AFB<sub>1</sub>-DNA binding was decreased by 40% at both AFB<sub>1</sub> levels with microsomes from BNF-treated rats.

Cytochrome P-450 content was twice as much in isolated hepatocytes from BNF-treated compared to

untreated controls (46.2  $\pm$  2.0 nmol/10<sup>8</sup> cells vs. 23.3  $\pm$  4.0 nmol/10<sup>8</sup> cells). Metabolism of AFB<sub>1</sub> was also examined in freshly isolated hepatocytes (Table 2). Data on hydroxylated metabolites represent both free and conjugated metabolites. Our preliminary studies indicated that conjugated metabolites comprised only 25% of total hydroxylated metabolites. Since conjugated metabolites were released as free hydroxylated metabolites by a combined treatment of  $\beta$ -glucuronidase and sulfatase, it is not possible to determine which conjugate was more predominant. In hepatocyte studies also, AFM<sub>1</sub> was the predominant hydroxylated metabolite of AFB<sub>1</sub> formed by control hepatocytes. Its formation was elevated by 120-160% above control levels by BNF-treatment of rats. In these studies, epoxidation of AFB<sub>1</sub> was examined by both AFB<sub>1</sub>-DNA binding and AFB<sub>1</sub>-SG conjugation. At low AFB<sub>1</sub> concentration (33 nM), BNF pretreatment of rats

**Table 3.** Effect of BNF pretreatment of rats on hepatic nuclear AFB<sub>1</sub>-DNA binding *in vivo*. Experimental details were as described in Materials and Methods' section. Results are given as means  $\pm$  SD of three analyses on individual livers from animals.

BNF Pretreatment 2.5 mg/100 g body weight	AFB <sub>1</sub> -DNA binding pmol/DNA
-	107 $\pm$ 13
+	62 $\pm$ 7 <sup>a</sup>

<sup>a</sup>Data statistically significant from untreated controls with *P* values < 0.02.

lowered AFB<sub>1</sub>-DNA binding by 60%. Concomitant with inhibition of AFB<sub>1</sub>-DNA binding, there appears to be an increase of 30% in AFB<sub>1</sub>-SG conjugation. However, this increase in AFB<sub>1</sub>-SG conjugation was not statistically significant. In one experiment, when AFB<sub>1</sub> metabolism was examined at higher AFB<sub>1</sub> concentration (2  $\mu$ M), BNF pretreatment lowered AFB<sub>1</sub>-DNA binding by 30% with an appreciable increase (70%) in AFB<sub>1</sub>-SG conjugation.

Data on hepatic nuclear AFB<sub>1</sub>-DNA binding *in vivo* are presented in Table 3. A single i.p. dose of BNF (2.5 mg/100 g body weight) 24 h before AFB<sub>1</sub> administration decreased AFB<sub>1</sub>-DNA binding by 40%.

## Discussion

Gurtoo's laboratory demonstrated that feeding BNF before and during AFB<sub>1</sub> treatment inhibited to a large extent AFB<sub>1</sub> hepatocarcinogenesis in the rat (Gurtoo *et al.*, 1985). The present study has shown that a single i.p. dose of BNF (25 mg/kg body weight) pretreatment of rats 24 h before AFB<sub>1</sub> administration inhibits genotoxic effect of AFB<sub>1</sub> as determined by hepatic AFB<sub>1</sub>-DNA binding *in vivo* (Table 3). These data are in agreement with our earlier preliminary data (Lotlikar, 1989) and those reported recently by others (Stresser *et al.*, 1994a).

Data on cytochrome P-450 content and AFB<sub>1</sub> hydroxylations with isolated microsomes and hepatocytes presented in this report are also compatible with microsomal studies from other investigators indicating that AFB<sub>1</sub> inactivation via enhanced AFM<sub>1</sub> hydroxylation as a major mechanism of BNF inhibition of AFB<sub>1</sub> hepatocarcinogenesis in the rat (Gurtoo *et al.*, 1985; Stresser *et al.*, 1994a). A similar mechanism has been proposed for BNF inhibition of AFB<sub>1</sub> hepatocarcinogenesis in rainbow trout (Goeger *et al.*, 1988). However, BNF pretreatment of hamsters, a species less susceptible to AFB<sub>1</sub>

hepatocarcinogenesis, has a contrasting effect. In this species, hepatic AFB<sub>1</sub>-DNA binding is increased *in vivo* and with isolated microsomes without significantly affecting AFM<sub>1</sub>, AFQ<sub>1</sub> and AFP<sub>1</sub> hydroxylations even though cytochrome P-450 levels are increased (Santhanam and Lotlikar, 1989).

Induced GSTs after PB or various antioxidant treatment of rats have been shown to play a significant role in inhibiting hepatic AFB<sub>1</sub>-DNA binding and AFB<sub>1</sub> hepatocarcinogenesis by inactivation of the reactive AFB<sub>1</sub>-epoxide via AFB<sub>1</sub>-SG conjugation (Degen and Neumann, 1981; Mandel *et al.*, 1987; Lotlikar, 1989; Jhee *et al.*, 1989; Lotlikar *et al.*, 1989; Kensler, 1994; Stresser *et al.*, 1994a). In the present study, there was no significant difference in AFB<sub>1</sub>-SG conjugate levels when hepatocytes were incubated at low levels of AFB<sub>1</sub> (33 nM). However, our present data indicate that this pathway of inactivation may be operative at higher concentrations of AFB<sub>1</sub>. Recent subcellular studies by Stresser *et al.* have suggested that enhanced detoxication of AFB<sub>1</sub>-epoxide via AFB<sub>1</sub>-SG conjugation due to enhanced levels of hepatic Yc<sup>2</sup> subunit of GST may be partly responsible for BNF protection of AFB<sub>1</sub> hepatocarcinogenesis in the rat (Stresser *et al.*, 1994a).

Previous investigations employing induction of *umu* gene in *Salmonella typhimurium* TA 1535/pSK1002 by activated carcinogens have indicated that constitutive forms of cytochrome P-450 have more important roles for the activation of AFB<sub>1</sub> than 3-methylcholanthrene, BNF and PB-inducible P-450 isozymes in rat liver (Shimada *et al.*, 1987, 1989; Imaoka *et al.*, 1992). Their studies have indicated that P-450 2C11, a major hepatic P-450 in male rat, is responsible for the highest activity in AFB<sub>1</sub> activation (Shimada *et al.*, 1987; Guengerich, 1988; Imaoka *et al.*, 1992). In the present study, both with isolated microsomes and hepatocytes, in spite of higher P-450 contents, AFB<sub>1</sub>-DNA binding was lower with BNF-treated rats. Even with 50-fold increase in AFB<sub>1</sub> concentration (2  $\mu$ M to 100  $\mu$ M), AFB<sub>1</sub>-epoxidation measured with AFB<sub>1</sub>-DNA binding was significantly lower with microsomes from BNF-treated rats. Shimada *et al.* (1989) also obtained lower activation of AFB<sub>1</sub> with liver microsomes from BNF treated rats compared to control microsomes when they examined *umu* gene response in a bacterial system. In contrast, previous data by Gurtoo *et al.* (1985) and recent data from another laboratory indicated no significant differences in AFB<sub>1</sub> epoxidation between microsomes from control and BNF treated rats (Stresser *et al.*, 1994b). However, their results of Western blot band densities of various P-450 forms from hepatic microsomes indicated that P-450 2C11 level was decreased by 50% in animals fed the diet containing BNF (Stresser *et al.*, 1994b). Other laboratories have also reported such a decrease in hepatic P-450 2C11 in rats pretreated with BNF

(Guengerich *et al.*, 1982; Shimada *et al.*, 1987; Imaoka *et al.*, 1992). On the basis of our present data and those of others (Guengerich *et al.*, 1982; Shimada *et al.*, 1987; Guengerich, 1988; Shimada *et al.*, 1989; Imaoka *et al.*, 1992; Stresser *et al.*, 1994a), we suggest an additional mechanism of inhibition of AFB<sub>1</sub> hepatocarcinogenesis by BNF pretreatment of rats. Inhibition of AFB<sub>1</sub>-DNA binding may be a direct result of lower AFB<sub>1</sub>-epoxidation due to lower levels of P-450 2C11 and other constitutive P-450s in livers of BNF treated rats. Additional studies are warranted to examine the contributions of these various mechanisms in inhibition of hepatic AFB<sub>1</sub>-DNA binding and hence AFB<sub>1</sub> hepatocarcinogenesis by BNF pretreatment of rats.

## Acknowledgements

We are indebted to Israel Beauchamps for expert assistance in preparation of this manuscript. This research was supported in part by grant CA-31641 awarded to P.D.L. and by grant CA-12227 from the National Cancer Institute, awarded to the Fels Institute.

## References

- Autrup, H., Seremet, T. Wakhisi, J. and Wasunna, A. (1987) Aflatoxin exposure measured by urinary excretion of aflatoxin B<sub>1</sub>-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. *Cancer Res.* 47: 3430-3433
- Burton, K. A. (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. *Biochem. J.* 62: 315-323
- Daoud, A. H. and Irving, C. C. (1977) Methylation of DNA in rat liver and intestine by dimethylnitrosamine and N-methylnitrosourea. *Chem. Biol. Interact.* 167: 135-143
- Degen, G. H. and Neumann, H. G. (1981) Differences in aflatoxin B<sub>1</sub>-susceptibility of rat and mouse are correlated with the capability *in vitro* to inactivate aflatoxin B<sub>1</sub>-epoxide. *Carcinogenesis* 2: 299-306
- Essigmann, J. M., Croy, R. G., Nadzan, A. M., Busby, W. F., Jr., Reinhold, V. N., Buchi, G. and Wogan, G. N. (1977) Structural identification of the major DNA adduct formed by aflatoxin B<sub>1</sub> *in vitro*. *Proc. Natl. Acad. Sci. U.S.A.* 74: 1870-1874
- Goeger, D. E., Shelton, D. W., Hendricks, J. D., Pereira, C. and Bailey, G. S. (1988) Comparative effect of dietary butylated hydroxyanisole and  $\beta$ -naphthoflavone on aflatoxin B<sub>1</sub> metabolism, DNA adduct formation and carcinogenesis in rainbow trout. *Carcinogenesis* 9: 1793-1800
- Guengerich, F. P. (1988) Perspectives in cancer research: roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. *Cancer Res.* 48: 2946-2954
- Guengerich, F. P., Dannan, G. A., Wright, S. T., Martin, M. V. and Kaminsky, L. S. (1982) Purification and characterization of liver microsomal cytochromes P-450: electrophoretic spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or  $\beta$ -naphthoflavone. *Biochemistry* 21: 6019-6030
- Gurtoo, H. L., Dahms, R. P. and Paigen, B. (1978) Metabolic activation of aflatoxins related to their mutagenicity. *Biochem. Biophys. Res. Commun.* 81: 965-972
- Gurtoo, H. L. and Dahms, R. P. (1979) Effects of inducers and inhibitors on the metabolism of aflatoxin B<sub>1</sub> by rat and mouse. *Biochem. Pharmacol.* 28: 3441-3449
- Gurtoo, H. L., Koser, P. L., Bansal, S. K., Fox, H. W., Sharma, S. D., Mulhern, A. F. and Pavelic, Z. P. (1985) Inhibition of aflatoxin B<sub>1</sub>-hepatocarcinogenesis in rats by  $\beta$ -naphthoflavone. *Carcinogenesis* 6: 675-678
- Imaoka, S., Ikemoto, S., Shimada, T. and Funae, Y. (1992) Mutagenic activation of aflatoxin B<sub>1</sub> by pulmonary, renal and hepatic cytochrome P450s from rats. *Mut. Res.* 269: 231-236
- Jhee, E. C., Ho, L. L., Tsuji, K., Gopalan, P. and Lotlikar, P. D. (1989) Effect of butylated hydroxyanisole pretreatment on aflatoxin B<sub>1</sub>-glutathione conjugation in isolated hepatocytes from rats. *Cancer Res.* 49: 1357-1360
- Kensler, T. (1994) The suppression of aflatoxin hepatocarcinogenesis by oltipraz: mechanisms and clinical opportunities. *Proc. Am. Assoc. Cancer Res.* 35: 696-697
- Lotlikar, P. D. (1989) Metabolic basis for susceptibility and resistance to aflatoxin B<sub>1</sub> hepatocarcinogenesis in rodents. *J. Toxicol. Toxin Rev.* 8: 97-109
- Lotlikar, P. D., Raj, H. G., Bohm, L. S., Ho, L. L., Jhee, E. C., Tsuji, K. and Gopalan, P. (1989) A mechanism of inhibition of aflatoxin B<sub>1</sub>-DNA binding in the liver by phenobarbital pretreatment of rats. *Cancer Res.* 49: 951-957
- Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951) Protein measurement with Folin phenol reagent. *J. Biol. Chem.* 193: 265-275
- Mandel, H. G., Manson, M. M., Judah, D. J., Simpson, J. L., Green, J. A., Forrester, L. M., Wolf, C. R. and Neal, G. E. (1987) Metabolic basis for the protection effect of the antioxidant ethoxyquin on aflatoxin B<sub>1</sub> hepatocarcinogenesis in the rat. *Cancer Res.* 47: 5218-5223
- Miller, J. A. and Miller, E. C. (1977) Ultimate chemical carcinogens as reactive mutagenic electrophiles. In *Origins of Human Cancer* (H. H. Hiatt, J. D. Watson and J. A. Winsten, eds.), pp. 605-627, Cold Spring Harbor, New York
- Moldeus, P., Högborg, J. and Orrenius, S. (1978) Isolation and use of liver cells. *Methods Enzymol.* 51: 60-71
- Newberne, P. M., and Butler, W. K. (1969) Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals. A review. *Cancer Res.* 29: 236-250
- Omura, T. and Sato, R. (1984) The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. *J. Biol. Chem.* 239: 2370-2378
- Ross, R. K., Yuan, J. M., Yu, M. C., Wogan, G. N., Qian, G. S., Tu, J. T., Groopman, J. D., Gao, Y. T. and Henderson, B. E. (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. *Lancet* 339: 943-946
- Santhanam, K. and Lotlikar, P. D. (1989) Effect of  $\beta$ -naphthoflavone on the metabolism of aflatoxin B<sub>1</sub> in hamsters. *Cancer Lett.* 45: 129-134
- Shimada, T., Iwasaki, M., Martin, M. V. and Guengerich, F. P. (1989) Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in

Salmonella typhimurium TA1535/pSK1002. *Cancer Res.* 49: 3218-3228

Shimada, T., Nakamura, S., Imaoka, S. and Funae, Y. (1987) Genotoxic and mutagenic activation of aflatoxin B<sub>1</sub> by constitutive forms of cytochrome P-450 in rat liver microsomes. *Toxicol. Appl. Pharmacol.* 91: 13-21

Stresser, D. M., Williams, D. E., Mclellan, L. I., Harris, T. M. and Bailey, G. S. (1994a) Indole-3-carbinol induces a rat liver glutathione transferase subunit (Yc2) with high activity toward aflatoxin B<sub>1</sub> exo-epoxide. Association with reduced levels of hepatic aflatoxin-DNA adducts *in vivo*. *Drug Metab. Disposition* 22: 392-399

Stresser, D. M., Bailey, G. S. and Williams, D. E. (1994b). Indole-3-

carbinol and  $\beta$ -naphthoflavone induction of aflatoxin B<sub>1</sub> metabolism and cytochromes P-450 associated with bioactivation and detoxication of aflatoxin B<sub>1</sub> in the rat. *Drug. Metab. Disposition* 22: 383-391

Van Rensburg, S. J., Cook-Mozaffari, P., Van Schalkwyk, D. J., Van DerWatt, J. J., Vincent, T. J. and Purchase, I. F. (1985) Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. *Br. J. Cancer* 51: 713-726

Wong, J. J. and Hsieh, D. P. H. (1976). Mutagenicity of aflatoxins related to their metabolism and carcinogenic potential. *Proc. Natl. Acad. Sci. U.S.A.* 73: 2241-2244